Early-onset breast cancer (EOBC) causes substantial loss of life and productivity, creating a major burden among women worldwide. We analyzed 1,265,548 Hapmap3 SNPs among a discovery set of 3,523 EOBC incident case and 2,702 population control women aged <=51 years. The SNPs with smallest P-values were examined in a replication set of 3,470 EOBC case and 5,475 control women. We also tested EOBC association with 19,684 genes by annotating each gene with putative functional SNPs, and then combining their P-values to obtain a gene-based P-value. We examined the gene with smallest P-value for replication in 1,145 breast cancer case and 1,142 control women. The combined discovery and replication sets identified 72 new SNPs associated with EOBC (P<4×10 −8 ) located in six genomic regions previously reported to contain SNPs associated largely with later-onset breast cancer (LOBC). SNP rs2229882 and 10 other SNPs on chromosome 5q11.2 remained associated (P<6×10 −4 ) after adjustment for the strongest published SNPs in the region. Thirty-two of the 82 currently known LOBC SNPs were associated with EOBC (P<0.05). Low power is likely responsible for the remaining 50 unassociated known LOBC SNPs. The gene-based analysis identified an association between breast cancer and the phosphofructokinase-muscle (PFKM) gene on chromosome 12q13.11 that met the genomewide gene-based threshold of 2.5×10 −6 . In conclusion, EOBC and LOBC appear to have similar genetic etiologies; the 5q11.2 region may contain multiple distinct breast cancer loci; and the PFKM gene region is worthy of further investigation. These findings should enhance our understanding of the etiology of breast cancer.
Introduction
Early-onset breast cancer (EOBC) leads to substantial loss of life and productivity, creating a major public health and economic burden in both developed and developing countries. Many patterns of breast cancer incidence, histopathological characteristics, clinical behavior and risk factors, including the increase in risk associated with a family history, differ between cases diagnosed during pre-menopausal and post-menopausal periods; a difference that has prompted speculation that there might be some genetic etiologies that are different for EOBC and later-onset breast cancer (LOBC) (1) (2) (3) (4) . For example, a study of Utah families estimated that the risk of developing BC for sisters of EOBC cases was 3.70 (95% written in C, R, Perl, and the Unix bash shell. Data quality control procedures are described in more detail in the Supplement and summarized in Table S3 . This table shows that 555,254 of the 1,298,078 SNPs remained after quality control, and that most SNPs were deleted because they appeared only on the 1M and 1M Omni chips that were used to type only 227 controls.
Analysis-We first identified principal components (PCs) representing axes of ancestral variation to adjust for population stratification (17) and imputed untyped SNPs using the HapMap3 data. We then conducted two SNP-based analyses and a gene-based analysis. The first SNP-based analysis consisted of SNP-specific logistic regressions for each of the 1,265,548 typed or imputed HapMap3 SNPs using BEAGLE (18). We checked for population stratification using graphical plots of test statistics and the lambda measure of overdispersion (19). We used an additive regression model in which the logit of EOBC risk was linearly related to the number of SNP minor alleles, and noted the SNPs with nominal P-values less than 4×10 −8 . These SNPs and their MAFs for cases and controls as well as the discovery set p-values are shown in Table S4 . The second SNP-based analysis was conducted to examine association between EOBC and each of the 82 breast-cancerassociated SNPs currently reported and validated in the literature. (We were unable to impute one SNP that was not polymorphic in the HapMap3 data.) Here we used SNP specific logistic regressions for each of the 82 SNPs in which the logit of EOBC risk was linearly related to the number of SNP risk alleles, as reported in the literature.
The gene-based analysis was conducted in two steps. First, we attempted to annotate each known human gene with one or more of the SNPs in the discovery set that could affect its expression and/or function. Then we combined the EOBC discovery set P-values of these expression-related SNPs into summary gene-based P-values. For step 1, we used eQTL mapping of SNPs to genes, as implemented in the online database SCAN (20, 21) and used the eQTL significance levels to quantify the likelihood that a SNP (or one in strong LD with it) regulates gene transcript levels (22) . That is, we assigned a SNP to a gene if the SNP encoded a missense, nonsense or frameshift (MNF) variant in the gene, or if it met our criteria for an expression-quantitative trait locus (e-QTL) SNP for the gene. While not all the SNPs annotated to a gene are likely to be functional, they are clearly enriched for those with functional consequence. We were able to annotate 19,684 genes with one or more putative functional SNPs, 11,040 of which were annotated with at least one e-QTL SNP. In step 2 we calculated a gene-based P-value for each of the 19,684 genes by combining the EOBCassociation P-values for all its putative functional SNPs using methods described elsewhere (23).
The Supplement contains additional details about both SNP-based and gene-based analyses.
Replication sets
Replication of SNP-based results-Primary genotype data were obtained from three early-onset breast cancer GWAS in populations of European ancestry (3, 24-28) as described in Supplementary Tables S5-S6 . For each typed or imputed SNP using ProbABEL (29), we combined the SNP-specific regression coefficients obtained for the discovery and replication sets using the commonly-deemed inverse-weighted summary statistic proposed by Cochran (30).
Replication of gene-based results-To replicate the gene-based association analyses, we used available GWAS data from the CGEMS breast cancer study of 1,145 Caucasian case women and 1,142 Caucasian control women aged 55-74 years. Details of subject selection, genotyping methods and QC analyses for CGEMS breast cancer project have been published (31, 32). The identical gene-based analytic method, described above and in the Supplement, was applied to the CGEMS data obtained from dbGaP. The gene-based Pvalues from both discovery and replication datasets were combined for the gene with smallest gene-based P-value in discovery data using Fisher's method for meta-analysis (33).
Further details of both the SNP-based and gene-based replication sets can be found in the Supplement.
Results

SNP-based analysis
Analysis of combined discovery and replication sets identified 96 SNPs from six chromosomal regions as associated with EOBC risk with P<4×10 −8 (the threshold for genome-wide significance at level 0.05 with 1.2 million independent tests). These results were not driven by data from a single site. The six regions lie on chromosomes 3p24.1, 5q11.2, 8q24, 10q26.13, 11q13.2 and 16q12.1. Previous GWASs have associated SNPs in these regions with (largely later-onset) breast cancer; however they have reported only 24 of these 96 SNPs (Table 1) (28, 31 , 32, 34-60). To investigate how many of the remaining 72 unpublished SNPs are independently associated with EOBC, we evaluated each of them using a regression model that also contained the published SNP in the region having the smallest P-value in the combined discovery and replication data (called the index SNP). These regressions identified 12 of the 72 SNPs as independently associated with EOBC at significance level P<0.001 (listed in bold type in Table 1 ). Eleven of these 12 SNPs are in the 5q11.2 region and almost all are within or near the MAP3K1 gene; eight are downstream of the published index SNP (Figure 1 ). The strongest of these SNPs, is rs2229882 with unadjusted P-value 1.02×10 −14 and squared correlation r 2 =0.10 with the published SNP rs889312 ( Figure 1 and Table 1 ).
To further explore the 5q11.2 association we examined 2,889 SNPs (278 typed and 2,611 imputed using 1KG data) within a 2Mb region centered at rs889312, the strongest published SNP in the region. We found rs7709971 to have the smallest P-value (1.01×10 −9 ). Adjusting for this SNP in bi-variate regressions did not produce strong new associations for any of the other SNPs in the region (results not shown). Table 2 shows 83 SNPs reported in the GWAS catalog http://www.genome.gov/26525384#1 as associated with breast cancer at P<4×10 −8 in studies of predominantly LOBC (28, 31, 32, 34-60). We used the discovery set to examine association between EOBC and the 82 SNPs that we could impute using HapMap3 and/or 1KG data. Table 2 shows that 32 SNPs were associated at P<0.05 (listed in bold type in the table). We also computed the probability that a test of size 0.05 using 3523 cases and 2702 controls would detect association with each of the 82 SNPs, given its published effect size as shown in the table. We found that the mean power to detect the 50 missed SNPs was 44%, appreciably lower than the mean power of 77% for the 32 we detected. Thus our failure to confirm the remaining 50 SNPs seems due to insufficient power to detect their small effect sizes. These results suggest that the genetic etiology of EOBC is not different than that of LOBC.
Association with known breast cancer SNPs
Gene-based analysis
Analysis of the discovery set identified the phosphofructokinase muscle-type (PFKM) gene on chromosome 12q13.11 region as associated with EOBC with P-value of 9×10 −7 , which meets the genome-wide threshold of P<2.5×10 −6 for the 19,684 statistical tests performed. This region is distinct from the regions 12q22 and 12q24 containing SNPs known to be associated with breast cancer (Table 2 ). When we repeated the same analysis using the predominantly LOBC breast cancer replication data from the CGEMS study, the PFKM gene also was associated with breast cancer (P=3×10 −2 ). Combined analysis of the two data sets yielded an overall gene-based Fisher's meta-P-value of 5×10 −7 for the PFKM gene. No other genes met the genome-wide significance threshold.
The association between PFKM and breast cancer risk was based on its annotation with the 35 putative functional SNPs shown in Table 3 . This set consists largely of trans e-QTL SNPs rather than MNF SNPs in the coding region of the gene. Nevertheless, we also found evidence implicating SNPs in the 1M region centered at the PFKM gene. We found that 27 of the 966 SNPs in this region that were included in the EOBC GWAS discovery set were associated with EOBC at P<0.01. These SNPs are listed in Figure 2 . Also shown in the To evaluate the statistical significance of this finding, we permuted subjects' case-control statuses 1000 times, and in each permutation we evaluated how many of the 966 SNPs were associated with EOBC at P<0.01. We found that none of the 1000 permutations yielded 27 or more such SNPs, giving a significance level of P<0.001. Most of the 27 EOBC-associated SNPs were located within other nearby genes, suggesting that EOBC risk could be due to some complex gene expression pattern in this gene-rich region (see Panels A and B of Figure 2 ). Panel C of the figure shows the correlations among the SNPs in the region.
Discussion
This study identified and replicated EOBC associations with 72 previously unpublished SNPs in six regions known to harbor variants affecting breast cancer risk. Twelve of the 72 SNPs remained associated with EOBC after adjusting for the SNP with smallest published P-value in the same region. Eleven of these 12 SNPs lie on chromosome 5q11.2 near the MAP3K1 gene. Their lack of strong correlation with the strongest published SNP rs889312 suggests the presence of multiple causal variants in this region. Future sequence-based studies, coupled with functional experiments, can exploit these associations to identify the causal variant(s) in the region.
We examined association between EOBC and 82 of the 83 common SNPs currently known to be associated with largely LOBC. We found evidence for association with only 32 (39%) of these SNPs. However comparison of detected and missed SNPs with respect to effect size and power suggests that this low confirmation rate reflects the inadequate power to detect the missed SNPs rather than systematic etiological differences between EOBC and LOBC. These findings suggest that the genetic factors responsible for breast cancer affect risk at all ages.
The gene-based GWAS analyses identified the PFKM gene region 12q13.11 as associated with breast cancer risk, independently of the 12q22 and 12q24 regions previously associated with breast cancer. PFKM, one of the three phospho-fructose-kinase (PFK) isoenzymes, is the key regulator of cellular glycolysis catalyzing the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate. Disabling PFKM mutations lead to glycogen storage diseases (especially type VII -Tarui's disease) as well as cardiac and hematological disorders (61) (62) (63) . The association of PFKM expression with breast cancer risk is plausible for several reasons. First, this gene is expressed in breast cancer cell lines (64) . Second, variants in the gene have been related to post-translational modifications, which have been shown to alter the metabolism and promote the growth of cancer cells (65) . Third, an association between breast cancer risk and this gene is consistent with observations that tumor cells can consume large amounts of glucose due to aberrant glucose metabolism, especially through a glycolytic pathway that produces lactate (65) . Finally, tumor suppressor protein p53 has been shown to suppress PFKM expression in model system (66) . Since the biology of the PFKM gene and its modulators and inhibitors are well characterized (67, 68) identification of PFKM gene region as a breast cancer susceptibility locus has potential translational implications for breast cancer prevention and treatment.
The present study has several strengths including its large sample size, its focus on EOBC, its homogenous Caucasian study population, and its novel gene-based analysis involving the functional characteristics of gene-related SNPs. Study limitations include use of somewhat different types of study populations between the discovery (population-based) and replication (both population-and clinic-based) phases, and our inability to replicate the gene-based analysis in an EOBC replication set due to lack of access to necessary relevant data from replication cohorts.
In conclusion, the study identified EOBC risks to be associated with 72 new SNPs in six chromosomal regions which were previously associated with LOBC risks. Eleven of the 72 SNPs, all on chromosome 5q11.2, were associated with EOBC independently of previously reported SNPs. These EOBC-associated SNPs may help in the search for causal variants in the 5q11.2 region. In addition, we found little evidence to support genetic heterogeneity between EOBC and LOBC. Finally, the gene-based analysis identified a region containing the key glycolysis regulation gene PFKM that is worthy of further investigation as a susceptibility locus for breast cancer in Caucasian women of all ages. Future studies need to determine whether the current findings apply to non-Caucasian women.
distributed by the Coriell Institute for Medical Research. The Colon Cancer Family Registry (CCFR) is supported by the National Cancer Institute, National Institutes of Health under RFA-CA-95-011. The content of this article does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government or the BCFR. The authors also are grateful for the use of data from the Database of Genotypes and Phenotypes (dbGaP), and thank all Investigators who contributed the phenotype data and DNA samples to the CGEMS project, and the National Cancer Institute, the primary funder of the CGEMS genome-wide association study. Manhattan plot of significance levels from combined discovery and replication data for SNPs in the 5q11.2 region. Y-axis shows minus log P-value for association with EOBC, Xaxis shows chromosomal position, and SNP color reflects its correlation with SNP rs889312 (SNP with smallest P-value in discovery set, marked by arrow). SNPs in red boxes are associated with P-value <0.001 from regression analyses adjusting for rs889312. Horizontal bar denotes genome-wide significance threshold P=4×10 −8 . Blue curve denotes recombination rate. Significance levels from discovery and replication sets for association of EOBC with 35 putatively functional PFKM SNPs
